Celularity Inc. Operating Lease Cost
Celularity Inc. (CELU) reported Operating Lease Cost of $3.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-04-30
- Celularity Inc. operating lease, cost for the quarter ending 2025-12-31 was $978.00K, a 0.00% change year-over-year.
- Celularity Inc. operating lease, cost for the quarter ending 2025-09-30 was $978.00K, a 0.00% change year-over-year.
- Celularity Inc. operating lease, cost for the quarter ending 2025-06-30 was $977.00K, a 0.00% change year-over-year.
- Celularity Inc. operating lease, cost for the quarter ending 2025-03-31 was $978.00K, a 0.00% change year-over-year.
- Celularity Inc. operating lease, cost for fiscal 2025 was $3.91M, a 0.00% change from fiscal 2024.
- Celularity Inc. operating lease, cost for fiscal 2024 was $3.91M, a 120016.71% increase from fiscal 2023.
- Celularity Inc. operating lease, cost for fiscal 2023 was $3.26K, a 99.89% decline from fiscal 2022.
- Celularity Inc. operating lease, cost for fiscal 2022 was $3.04M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $978.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $1.96M derived: sum of 2 quarters · filed 2026-04-30 | $2.93M derived: sum of 3 quarters · filed 2026-04-30 | $3.91M 10-K · filed 2026-04-30 | |
| 2025-09-30 | $978.00K 10-Q · filed 2025-11-14 | $1.96M derived: sum of 2 quarters · filed 2025-11-14 | $2.93M 10-Q · filed 2025-11-14 | $3.91M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-06-30 | $977.00K 10-Q · filed 2025-08-29 | $1.96M 10-Q · filed 2025-08-29 | $2.93M derived: sum of 3 quarters · filed 2026-04-30 | $3.91M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-03-31 | $978.00K 10-Q · filed 2025-08-29 | $1.96M derived: sum of 2 quarters · filed 2026-04-30 | $2.93M derived: sum of 3 quarters · filed 2026-04-30 | $3.91M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $978.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $1.96M derived: sum of 2 quarters · filed 2026-04-30 | $2.93M derived: sum of 3 quarters · filed 2026-04-30 | $3.91M 10-K · filed 2026-04-30 | $3.91K 10-K · filed 2025-05-08 |
| 2024-09-30 | $978.00K 10-Q · filed 2025-11-14 | $1.96M derived: sum of 2 quarters · filed 2025-11-14 | $2.93M 10-Q · filed 2025-11-14 | $658.26K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $977.00K 10-Q · filed 2025-08-29 | $1.96M 10-Q · filed 2025-08-29 | -$319.74K derived: sum of 3 quarters · filed 2025-08-29 | $439.26K derived: sum of 4 quarters · filed 2025-08-29 | |
| 2024-03-31 | $978.00K 10-Q · filed 2025-08-29 | -$1.30M derived: sum of 2 quarters · filed 2025-08-29 | -$537.74K derived: sum of 3 quarters · filed 2025-08-29 | $222.26K derived: sum of 4 quarters · filed 2025-08-29 | |
| 2023-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$1.52M derived: sum of 2 quarters · filed 2025-05-08 | -$755.74K derived: sum of 3 quarters · filed 2025-05-08 | $3.26K 10-K · filed 2025-05-08 | $3.26M 10-K · filed 2024-07-30 |
| 2023-09-30 | $759.00K 10-Q · filed 2024-12-06 | $1.52M derived: sum of 2 quarters · filed 2024-12-06 | $2.28M 10-Q · filed 2024-12-06 | $3.04M derived: sum of 4 quarters · filed 2024-12-06 | |
| 2023-06-30 | $760.00K 10-Q · filed 2024-11-07 | $1.52M 10-Q · filed 2024-11-07 | $2.28M derived: sum of 3 quarters · filed 2024-11-07 | $3.04M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-03-31 | $760.00K 10-Q · filed 2024-10-16 | $1.52M derived: sum of 2 quarters · filed 2024-10-16 | $2.28M derived: sum of 3 quarters · filed 2024-10-16 | $3.04M derived: sum of 4 quarters · filed 2024-10-16 | |
| 2022-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $1.52M derived: sum of 2 quarters · filed 2024-07-30 | $2.28M derived: sum of 3 quarters · filed 2024-07-30 | $3.04M 10-K · filed 2024-07-30 | |
| 2022-09-30 | $759.00K 10-Q · filed 2024-01-03 | $1.52M derived: sum of 2 quarters · filed 2024-01-03 | $2.28M 10-Q · filed 2024-01-03 | ||
| 2022-06-30 | $759.00K 10-Q · filed 2023-08-14 | $1.52M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $760.00K 10-Q · filed 2023-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |